|
Bioassay-based screening
of myxobacteria producing antitumor secondary metabolites
Wen-Jie Guo1,3, Feng-Jie Cui1 and Wen-Yi
Tao1,2*
1School
of Biotechnology, Southern Yangtze University, Wuxi, P.R.
China, 214122.
2The
Key Laboratory of Industrial Biotechnology, Ministry of
Education, Southern Yangtze University.China.
3Gujing
Group, Bozhou, Anhui Province, P.R.China, 236820.
*Corresponding author. E-mail:
wytao1946@163.com.
Tel: +86-510-85918205, 85979966.
Accepted 12 November, 2007 |
|
Myxobacteria are gliding gram-negative bacteria and a class
of prokaryote with complicated multicellular behaviors and
morphogenesis. Reports show that myxobacteria generally
produce large families of secondary metabolites with various
bioactivities, such as antifungal and anti-tumor
activities. In this paper, two strains producing
metabolites with high anticancer bioactivity to 5 tumor cell
lines were screened from over 370 isolated samples by
adopting cell culturing technology and cell toxicity tests.
The strains were identified as genus polyangium (Polyangium
vitellinum and Sorangium cellulosum), named
JSW103 and AHB125, based on the morphology of vegetative
swarms, fruiting bodies, vegetative cells and myxospores.
IC50 values of JSW103 to tumor cell lines B16 and
SGC7901 were 0.2715 μg ml-1 and 4.1924 μg ml-1,
respectively, while for AHB125 metabolites to tumor cell
lines B16 and SGC7901, the values were 0.0082 μg ml-1 and
0.036 μg ml-1, respectively.
Key
words: Antitumor activity, bioassay-based screening, IC50,
myxobacteria, secondary metabolites. |
